Breast, prostate, and melanoma patients experienced dramatic tumor regression and long-lasting remission — without chemotherapy.
Fenbendazole (FBZ) is a low-cost veterinary antiparasitic drug that has gained global attention as a potential anticancer therapy. Like ivermectin—another antiparasitic widely repurposed in research and clinical practice for its potent anti-tumor effects—fenbendazole appears to work far beyond its original veterinary use.
NEW STUDY – Ivermectin Shows Striking Anticancer Potential and Remarkable Safety
By Nicolas Hulscher, MPH
Preclinical studies show fenbendazole disrupts cancer cell survival through multiple pathways, but until now, human evidence has been scarce.
A newly published case series by Dr. William Makis et al in Case Reports in Oncology presents three remarkable patients with advanced, stage IV cancers (breast, prostate, and melanoma) who self-administered Fenbendazole outside conventional oncology protocols. All three achieved either complete or near-complete remission — sustained for up to three years — without chemotherapy:
